Myers Bigel, P.A.
Immune profiling and minimal residue disease following stem cell transplantation in multiple myeloma
The present invention provides methods for determining the level or status of minimal residue disease (MRD) in a multiple myeloma (MM) patient including analyzing peripheral natural killer (NK), NK-T and T cell distribution and/or activation, and quantifying inflammatory cytokines, chemokines and growth factors in a biological sample obtained from an MM patient to provide a peripheral immune profile; and obtaining a level or status of MRD in the MM patient from the peripheral immune profile, wherein if the peripheral immune profile exceeds a pre-determined threshold, the MM patient is positive for MRD.
The Charlotte Mecklenburg Hospital Authority
G G G G G G G G G G
G01N G01N G01N G01N G01N G01N G01N G01N G01N G01N
inventional additional inventional inventional additional inventional additional inventional additional additional
Manisha Qing Saad Z. David M.
Bhutani Zhang Usmani Foureau